Conclusions
DISEASE, COVID-19 PNEUMONIA, SECONDARY, INFLAMMATION
The findings of this randomized clinical trial suggest that the use of anakinra together with SoC does not prevent the need for mechanical ventilation or reduce mortality risk compared with SoC alone in hospitalized patients with severe COVID-19 pneumonia and hyperinflammation. Although the primary and key secondary outcomes were not met, anakinra may have a role as an early treatment for patients with less-severe disease and inflammation.